{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:07:12Z","timestamp":1790179632853,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.fjurol.2025.103011","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:44:58Z","timestamp":1760809498000},"page":"103011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["French recommendations of the AFU Oncology Committee for Bladder Cancer: Update 2025"],"prefix":"10.1016","volume":"35","author":[{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Etienne","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-077X","authenticated-orcid":false,"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Bajeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-1448","authenticated-orcid":false,"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-3295","authenticated-orcid":false,"given":"Priscilla","family":"L\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriane","family":"Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-1341","authenticated-orcid":false,"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.fjurol.2025.103011_bib0105","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/iub.2309","article-title":"Detection of a novel mutation in a Tunisian child with polycystic kidney disease","volume":"72","author":"Abdelwahed","year":"2020","journal-title":"IUBMB Life"},{"issue":"5","key":"10.1016\/j.fjurol.2025.103011_bib0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.purol.2022.01.004","article-title":"[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, and Epirubicin, and BCG for non-muscle invasive bladder cancer]","volume":"32","author":"Leon","year":"2022","journal-title":"Prog Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2025.103011_bib0115","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.euo.2025.06.003","article-title":"The evolving landscape of systemic immunotherapy for bacillus calmette-guerin-naive high-risk non-muscle-invasive bladder cancer: at the edge of a tsunami?","volume":"8","author":"Gabriel","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"10.1016\/j.fjurol.2025.103011_bib0120","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.fjurol.2025.103011_bib0125","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1038\/s41598-018-26002-6","article-title":"Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Ge","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.fjurol.2025.103011_bib0130","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.euf.2021.07.015","article-title":"Survival outcomes after immediate radical cystectomy versus conservative management with Bacillus Calmette-Guerin among T1 high-grade micropapillary bladder cancer patients: results from a multicentre collaboration","volume":"8","author":"Lonati","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.fjurol.2025.103011_bib0135","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JU.0000000000002266","article-title":"Role of lymphadenectomy during radical cystectomy for nonmuscle-invasive bladder cancer: results from a multi-institutional experience","volume":"207","author":"Khanna","year":"2022","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.103011_bib0140","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the Randomized Controlled BRAVO-Feasibility Study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.fjurol.2025.103011_bib0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102496","article-title":"Differential prognosis and response of Denovo vs. secondary muscle-invasive bladder cancer: an updated systematic review and meta-analysis","volume":"13","author":"Pones","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.fjurol.2025.103011_bib0150","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7150\/ijms.49228","article-title":"Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: An updated meta-analysis","volume":"18","author":"Zheng","year":"2021","journal-title":"Int J Med Sci"},{"issue":"6","key":"10.1016\/j.fjurol.2025.103011_bib0155","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.fjurol.2025.103011_bib0160","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.103011_bib0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2025.103011_bib0170","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/JU.0000000000003836","article-title":"Impact of Divergent Differentiation and\/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial","volume":"211","author":"Allory","year":"2024","journal-title":"J Urol"},{"issue":"19","key":"10.1016\/j.fjurol.2025.103011_bib0175","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.fjurol.2025.103011_bib0180","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2025.103011_bib0185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials","volume":"81","year":"2022","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.fjurol.2025.103011_bib0190","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.fjurol.2025.103011_bib0195","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.fjurol.2025.103011_bib0200","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:46:37Z","timestamp":1790178397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393025001585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950393025001585"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.103011","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French recommendations of the AFU Oncology Committee for Bladder Cancer: Update 2025","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.103011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103011"}}